Osteoarthritis is a common, degenerative joint disease with significant socio-economic
impact worldwide. There are currently no disease-modifying drugs available to treat the …

osteoarthritis (OA) is treated with the intra-articular injection of steroids such as
dexamethasone (DEX) to provide short-term pain management. However, DEX treatment …

Osteoarthritis (OA) is a common chronic joint pathology that has become a predominant
cause of disability worldwide. Even though the origin and evolution of OA rely on different …

Intra-articular (IA) injection is an attractive route of administration for the treatment of
osteoarthritis (OA). However, free drugs injected into the joint space are rapidly cleared and …

Osteoarthritis is one of the foremost disabling disorders in the world. There is no definitive
treatment to prevent the progression of osteoarthritis. Hence, palliative treatment aims at …

Intraarticular (IA) injections provide the opportunity to deliver biologics directly to their site of
action for a local and efficient treatment of osteoarthritis. However, the synovial joint is a …

Osteoarthritis (OA) is a complex multi-target disease with an unmet medical need for the
development of therapies that slow and potentially revert disease progression. Intra-articular …

Noninfectious arthritis (NIA) comprises a class of chronic and progressive inflammatory
disorders that require early‐stage management to prevent disease progression. The most …

Glycol chitosan/fucoidan nanogels loaded with anti-inflammatory peptide KAFAK (GC/Fu@
KAFAK NGs) were fabricated based on the electrostatic interaction and genipin cross-linking …

Current drug delivery approaches for the treatment of cartilage disorders such as
osteoarthritis (OA) remain inadequate to achieve sufficient drug penetration and retention in …